You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
|
|---|---|
| Published in |
Cardiovascular Diabetology, February 2017
|
| DOI | 10.1186/s12933-017-0499-5 |
| Pubmed ID | |
| Authors |
James Xu, Rohan Rajaratnam |
| Abstract |
Patients with type 2 diabetes mellitus have a twofold increased risk of cardiovascular mortality compared with non-diabetic individuals. There is a growing awareness that glycemic efficacy of anti-diabetic drugs does not necessarily translate to cardiovascular safety. Over the past few years, there has been a number of trials evaluating the cardiovascular effects of anti-diabetic drugs. In this review, we seek to examine the cardiovascular safety of these agents in major published trials. Metformin has with-stood the test of time and remains the initial drug of choice. The sulfonylureas, despite being the oldest oral anti-diabetic drug, has been linked to adverse cardiovascular events and are gradually being out-classed by the various other second-line agents. The glitazones are contraindicated in heart failure. The incretin-based drugs have been at the fore-front of this era of cardiovascular safety trials and their performances have been reassuring, whereas the meglitinides and the alpha-glucosidase inhibitors still lack cardiovascular outcomes data. The sodium glucose cotransporter-2 inhibitors are an exciting new addition that has demonstrated a potential for cardiovascular benefit. Many of the currently available oral anti-diabetic agents have clinically relevant cardiovascular effects. The optimal approach to the reduction of cardiovascular risk in diabetic patients should focus on aggressive management of the standard cardiovascular risk factors rather than purely on intensive glycemic control. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Guinea | 1 | 33% |
| Saudi Arabia | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
| Scientists | 1 | 33% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 132 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 19 | 14% |
| Student > Master | 17 | 13% |
| Other | 12 | 9% |
| Student > Postgraduate | 10 | 8% |
| Student > Doctoral Student | 9 | 7% |
| Other | 21 | 16% |
| Unknown | 44 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 8% |
| Nursing and Health Professions | 10 | 8% |
| Agricultural and Biological Sciences | 5 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Other | 2 | 2% |
| Unknown | 48 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2017.
All research outputs
#15,327,026
of 25,728,855 outputs
Outputs from Cardiovascular Diabetology
#845
of 1,689 outputs
Outputs of similar age
#226,714
of 426,723 outputs
Outputs of similar age from Cardiovascular Diabetology
#17
of 27 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,689 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 426,723 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.